Can a patient with myelodysplastic syndrome receive red blood cell transfusions for anemia?

Yes, patients with MDS can and should receive red blood cell transfusions for symptomatic anemia

Red blood cell transfusions are a standard and often essential treatment for anemia in MDS patients, with approximately 40% of MDS patients relying on RBC transfusions as their sole therapeutic option for anemia. 1, 2

When to Transfuse

The decision to transfuse should be based on clinical symptoms and comorbidities, not just hemoglobin numbers alone 2, 3:

• All patients with hemoglobin <8 g/dL should receive RBC transfusion 3
• Patients with symptomatic milder anemia should also receive transfusion 3
• Higher thresholds (9-10 g/dL) are appropriate for patients with:
  • Cardiovascular comorbidities
  • Poor functional tolerance
  • Compromised quality of life
  • Elderly patients who remain active 2

Transfusion Strategy

Transfuse sufficiently to raise hemoglobin above 10 g/dL rather than giving minimal amounts 2, 1. This approach:

• Limits the effects of chronic anemia
• Improves quality of life
• Reduces cardiac workload
• May decrease the frequency of transfusion visits

The primary goal is preserving quality of life and avoiding anemia-related symptoms and ischemic organ damage 1, 3.

Critical Caveat: Iron Overload Management

While RBC transfusions are necessary and appropriate, you must anticipate and manage iron overload:

Each unit of RBCs contains 200-250 mg of iron, and iron overload can occur after 20-25 transfusions 3. This is particularly important because:

• Transfusion dependency is associated with shorter survival and increased risk of leukemic transformation 1
• Secondary iron overload (ferritin >1,000 ng/mL) significantly worsens survival, with a 30% increase in hazard for every 500 ng/mL increase above this threshold 1
• Iron overload causes cardiac disease, liver dysfunction, and endocrine problems 1

Iron Chelation Recommendations

Consider iron chelation therapy for patients with:

• Low or intermediate-1 risk MDS (better prognosis, longer survival)
• Who have received 20-60 RBC units
• Serum ferritin >1,000-2,500 ng/mL
• Candidates for allogeneic stem cell transplantation (chelate early, as elevated ferritin increases transplant-related mortality) 2, 3

Common Pitfalls to Avoid

1. Don't withhold transfusions due to fear of iron overload - the immediate benefit to quality of life and organ function outweighs this concern, which can be managed with chelation 1

2. Don't use arbitrary hemoglobin triggers alone - assess symptoms and comorbidities 3

3. Don't undertransfuse - giving insufficient amounts leads to more frequent visits and persistent symptoms 2

4. Don't ignore alloimmunization risk - approximately 8% of MDS patients develop RBC antibodies, particularly in the Rh system; communicate regularly with your blood bank 4, 5

5. Monitor ferritin levels regularly in transfusion-dependent patients to guide chelation decisions 1

The Evidence Hierarchy

The most recent guideline evidence from NCCN 2025 6, ESMO 2014 2, and European LeukemiaNet 2013 3 all consistently support RBC transfusion as standard care. The consensus statements on iron overload 1 emphasize that while transfusions are necessary, iron chelation should be part of the long-term management strategy for transfusion-dependent patients with favorable prognosis.